MARLBOROUGH, Mass.--(BW HealthWire)--Feb. 6, 2002--Cetek Corporation announced today that it has signed an agreement with Tularik Inc. (Nasdaq: TLRK - news) to develop assays and perform high throughput screens for the discovery of lead compounds. Financial terms were not disclosed.
``Tularik has built a strong pipeline of novel therapeutics based on new disease targets,'' said James. N. Little, President of Cetek. ``We are proud that Tularik recognizes the power of our CE assay technology and screening expertise, and we look forward to identifying promising leads to fuel their discovery efforts.''
Cetek has demonstrated that its core CE Assay is able to efficiently identify and rank the affinity of synthetic and natural product small molecules to therapeutic target proteins in a high-throughput environment. Cetek has screened over 6 million compounds against 120 targets in the last two years of operation. Cetek has doubled its screening capacity over the last three months to accommodate increased demand in contract screening and to accommodate demand from the Cetek Natural Products program. Ongoing screening collaborations at Cetek include: Pharmacia, Genome Therapeutics, Lexicon Genetics, Millennium Pharmaceuticals, Essential Therapeutics, Johnson & Johnson and Schering-Plough plus others in North America, Europe and Japan.
About Cetek
Cetek Corporation is a drug discovery company that is unlocking new reservoirs of natural compound diversity for the creation of novel therapeutics. Cetek integrates expertise in automation, engineering and novel strategies in natural product chemistry to utilize its capillary electrophoresis technology as a highly sensitive and robust technology for high throughput screening and compound isolation. Cetek also employs its automated CE Assay(TM) to provide contract research for pharmaceutical and biotechnology partners to advance their own synthetic and natural product drug discovery programs. Visit Cetek's website at cetek.com.
(Interesting list of customers for Cetek...) |
